	_			
NR	C	FΩ	RM	374

## U.S. NUCLEAR REGULATORY COMMISSION

PAGE \_\_1\_\_OF \_3\_ PAGES

Amendment No. 21

## **MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s)

ap <sub>l</sub>	plicat ende	ole Part(s). This license shall be deemed to	o contain the condi	itions specified in Sectio	in accordance with the regulations of the in 183 of the Atomic Energy Act of 1954, as atory Commission now or hereafter in effect		
-		Licensee	0100	In accordance with	n letter dated		
1	Mai	rcy Memorial Hospital		July 27, 2009,			
				3. License number 21-18816-01 is amended in its entirety to read as follows:			
2.		3 North Macomb Street		4. Expiration date September 30, 2011			
	Mor	nroe, MI 48161		5. Docket No. 030-14 Reference No.	<del>1</del> 210		
6.		product, source, and/or special nuclear terial	7. Chemical ar	nd/or physical form 8	Maximum amount that licensee may possess at any one time under this license		
	A.	Any byproduct material permitted by 10 CFR 35.100	A. Any		A. As needed		
	B.	Any byproduct material permitted by 10 CFR 35.200	B. Any		B. As needed		
	C.	Any byproduct material permitted by 10 CFR 35.300	C. Any		C. As needed (not to exceed 1 curie of iodine-131)		
	D.	Any byproduct material permitted by 10 CFR 31.11	D. Prepac	ckaged Kits	D. As needed		
	E.	lodine-125 permitted by 10 CFR 35.400	•	Sources Brachytherapy STM 1251	E. 500 millicuries		
	F.	Palladium-103 permitted by 10 CFR 35.400	Model (		F. 500 millicuries		

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION	PA	AGE	2	of	3	PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET		License Number 21-18816-01					
		Docket or Reference Number 030-14210					
		Amendment No. 21					

- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. In vitro studies.

E. and F. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

## CONDITIONS

- 10. Licensed material may be used at the licensee's facilities located at 718 North Macomb Street, Monroe, Michigan.
- 11. The Radiation Safety Officer for this license is Michael Arsenault, D.O.
- 12. Licensed material is only authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
  - B. The following individuals are authorized users for medical use as indicated:

Ronald C. Lutsic, D.O.	10 CFR 35.400
Gerling Sauter, M.D.	10 CFR 35.100, 35.200 and 35.300.
Reza Abghari, M.D.	10 CFR 35.100, 35.200 and 35.300.
Bruno Borin, D.O.	10 CFR 35.100 and 35.200.
Michael Arsenault, D.O.	10 CFR 35.100, 35.200 and 35.300.
Authorized Users	Material and Use

- 13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
- 14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

- 15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
  - A. Application dated March 28, 2001; and,
  - B. Letter received April 3, 2001 (excluding Quality Management Program (QMP)), and;
  - C. Letters dated June 4, 2003, facsimile transmitting letters dated August 19, 2003 and August 28, 2003, April 5, 2006, July 17, 2007, October 7, 2007, January 23, 2008, and August 26, 2008, July 27, 2009; and
  - D. Facsimile dated June 14, 2006; and
  - E. Facsimile letter dated December 19, 2007.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

AUG 3 1 2009

Ву\_

James R. Mullauer, M.H.S. Materials Licensing Branch

Region III